Most email marketers build lists fast and blast often. In biotech and pharma, every list needs documented consent and every send needs to clear medical, legal, and regulatory review before it goes out. We build HCP and patient email programs around that reality instead of fighting it.
The Problem
Your HCP list was never actually opted in
Business cards scanned at a conference booth and sample-request forms are not the same thing as documented consent to receive marketing email. When your list is built this way, deliverability tanks, complaint rates climb, and your compliance team eventually asks you to explain where every address came from. Most teams find out they can't answer that question until it's too late to fix cheaply.
MLR review turns every campaign into a six-week project
A marketing team used to writing and shipping an email in a day hits a wall the first time a campaign needs medical, legal, and regulatory sign-off. Without a template library pre-cleared for common claim types, every send starts from a blank page and a blank review queue. Programs stall, sends get pushed to the next quarter, and the calendar you built in January is dead by March.
Specialty and primary care prescribers get the same email
A rheumatologist prescribing your biologic weekly and a primary care physician who sees your drug once a year need different content, different frequency, and different calls to action. Sending both groups the same campaign wastes the specialist's attention and over-markets to the generalist. Engagement drops for both segments and you can't tell which one is actually the problem.
Patient email touches HIPAA-adjacent data with no real handling policy
Adherence reminders and patient support program communications require you to track health status information you did not need for a standard DTC list. Without a documented data handling and consent policy specific to patient email, you are one audit away from a finding that halts the whole program. Legal will not let this scale until the policy exists in writing, not just in someone's head.
How We Help
We start by auditing what you actually have: your current HCP and patient lists, how each address was captured, what consent language exists (if any), and what your MLR review process looks like today. Most biotech and pharma teams we meet have never mapped this end to end. The audit gives us a clear picture of what's usable, what needs re-permissioning, and where the review bottleneck actually lives.
From there we build the segmentation model your prescriber and patient audiences actually require. HCP lists get split by specialty versus primary care, by prescribing volume where you have it, and by conference or channel of origin. Patient lists get split by program stage, adherence status, and consent scope. This is not a generic persona exercise. It's built off the fields your CRM and sample-request systems already capture.
We design the consent capture flow next. This means opt-in language for conference booths, sample request forms, and patient support program enrollment that legal can actually approve and that your list-growth team can actually execute at a booth or in a clinic. Compliant list growth in this vertical is slower than DTC. We build a pace you can sustain instead of a pace that looks good in a Q1 slide and dies by Q2.
On execution, we build a template library that's been through MLR once and can run the review clock down for every send that follows. Claim language, fair balance statements, and ISI placement get locked into templates so your review team is checking for drift, not starting from zero. This is the single biggest lever for shrinking your campaign cycle time.
We also build the patient email track separately from HCP, with its own consent scope and its own data handling documentation. Adherence reminders and program communications get written to avoid triggering health-status data handling requirements you don't need to take on, and where you do need to handle that data, the policy is written down before the first send, not after an audit flags it.
Measurement in this channel is different too. Open and click rates matter less than they do in DTC. We track MLR review cycle time, opt-in-to-active-subscriber conversion, specialty versus primary care engagement split, and patient program enrollment-to-adherence-reminder response. These are the numbers that tell you whether the program is actually working, not just whether people are opening email.
By day 90 you have a documented consent framework, a segmented list built on real data, a pre-cleared template library, and a review cycle that runs in days instead of weeks. That's the infrastructure. What you do with it compounds every quarter after.
What we deliver
- Consent audit and re-permissioning plan – a full accounting of your current HCP and patient lists, what consent exists, and what needs to be fixed before you can send to it
- Prescriber and patient segmentation model – specialty vs. primary care splits, patient program stage tiers, built off fields your existing systems already capture
- MLR-ready template library – claim language, fair balance, and ISI placement pre-cleared so future sends move through review faster
- Patient data handling policy – written documentation for adherence and patient support communications that legal can sign off on before scale, not after an incident
In biotech and pharma, the email program that wins isn't the one with the best subject lines. It's the one whose consent records and review process don't fall apart the first time compliance asks a hard question.
Our Methodology
We run every engagement as a 90-day sprint, not an open-ended retainer. The first 30 days are audit and design: consent status, segmentation model, and MLR workflow mapping. The next 30 are build: templates, consent capture flows, and the first campaigns moving through review. The final 30 are execution and measurement, where we run live sends, track cycle time and engagement by segment, and hand you a system you can operate without us in the room.
This isn't a generic email marketing playbook with a pharma logo pasted on it. The consent and review constraints in this vertical are structural, not cosmetic, and a program designed without them in mind will get rebuilt within a year regardless of how good the copy is. We design for the constraint from day one so the program you have in month three is the same one you're still running in month eighteen.
How We Work
Days 1-30: we audit your existing HCP and patient email infrastructure, map your MLR review process end to end, and design the segmentation model and consent capture flow. You get a written assessment and a build plan before we touch a single template.
Days 31-60: we build the template library, the consent language for conference and sample-request capture, and the patient data handling policy. Your MLR reviewers are involved in this phase directly, not handed a finished product to approve cold. This is what makes the review cycle faster later – they've already seen and shaped the structure.
Days 61-90: we run live campaigns through the new system, track cycle time and segment-level engagement, and adjust based on what the data shows. By the end of this phase you have a working program and the internal muscle to keep running it.
Our team works directly with your marketing, medical affairs, and legal stakeholders on a weekly cadence. We're not a black box agency that disappears between deliverables. Expect direct access to whoever is doing the work, not an account manager relaying messages.
- A documented, audit-ready consent framework for HCP and patient lists
- A materially shorter MLR review cycle for standard campaign types
- A segmentation model that lets you measure engagement by specialty, prescriber type, and patient program stage instead of one blended number
If your biotech & pharma company needs email marketing leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How much does an HCP and patient email program cost to build?
Most biotech and pharma email engagements with us run $15,000 to $40,000 per month depending on how much of the consent and segmentation infrastructure already exists. A company starting from a cold list and no MLR-ready templates sits at the higher end. A company with clean consent records that just needs segmentation and template work moves faster and costs less.
How long until we see a working email program?
The 90-day sprint gets you from audit to a live, running program with pre-cleared templates and a faster review cycle. Full list re-permissioning can take longer if your current list has significant consent gaps, since fixing that requires new capture events at conferences or through patient enrollment, not just a system change.
Do you work inside our existing marketing and medical affairs teams, or replace them?
We work inside your team. Your MLR reviewers, medical affairs contacts, and marketing staff are part of the build from week one, not handed a finished system to approve. We're a fractional extension of your team, not a vendor that disappears after delivery.
How is this different from hiring a pharma marketing agency?
Agencies typically sell a campaign calendar and a content plan. We build the consent and review infrastructure underneath the campaign calendar, which is the part that actually determines whether your program can scale. Without that foundation, the calendar collapses the first time a campaign gets stuck in MLR for six weeks.
How do you measure ROI on an HCP or patient email program?
We track MLR review cycle time, opt-in-to-active-subscriber conversion, engagement split by specialty versus primary care, and patient enrollment-to-response rates on adherence communications. Standard open and click benchmarks from DTC email don't translate cleanly here, so we build the scorecard around the metrics that reflect how this channel actually functions in a regulated environment.
What kind of biotech or pharma company is the right fit for this?
Series A through growth-stage companies with a commercial or near-commercial asset, at least one active HCP or patient communication channel already in motion, and a marketing team that's hit the MLR bottleneck are the best fit. If you don't yet have an asset close to commercialization, this program is premature – talk to us about growth strategy first.
